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Abstract
Absence of leptin has been associated with reduced skeletal muscle mass in leptin-deficient ob/ob mice. The aim of our
study was to examine the effect of leptin on the catabolic and anabolic pathways regulating muscle mass. Gastrocnemius,
extensor digitorum longus and soleus muscle mass as well as fiber size were significantly lower in ob/ob mice compared to
wild type littermates, being significantly increased by leptin administration (P,0.001). This effect was associated with an
inactivation of the muscle atrophy-related transcription factor forkhead box class O3 (FoxO3a) (P,0.05), and with a decrease
in the protein expression levels of the E3 ubiquitin-ligases muscle atrophy F-box (MAFbx) (P,0.05) and muscle RING finger 1
(MuRF1) (P,0.05). Moreover, leptin increased (P,0.01) protein expression levels of peroxisome proliferator-activated
receptor c coactivator-1a (PGC-1a), a regulator of muscle fiber type, and decreased (P,0.05) myostatin protein, a negative
regulator of muscle growth. Leptin administration also activated (P,0.01) the regulators of cell cycle progression
proliferating cell nuclear antigen (PCNA) and cyclin D1, and increased (P,0.01) myofibrillar protein troponin T. The present
study provides evidence that leptin treatment may increase muscle mass of ob/ob mice by inhibiting myofibrillar protein
degradation as well as enhancing muscle cell proliferation.
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Introduction
Leptin, the product of the ob gene, is a hormone that acts as an
afferent signal in a negative-feedback loop regulating the size of
adipose tissue mass [1]. In addition to its function as a satiety
factor, leptin regulates several physiological processes, such as
glucose and lipid metabolism, immunity, reproduction and blood
pressure homeostasis [2,3]. Skeletal muscle also constitutes an
important target for leptin [3,4]. Several studies have reported that
leptin-deficient ob/ob mice display a reduced skeletal muscle mass
[5] compared with their lean littermates. However, the mecha-
nisms whereby leptin regulates muscle growth are poorly
understood.
Skeletal muscle mass and composition are critical for exercise,
energy expenditure and glucose metabolism. Although the
underlying mechanisms involved in the development of muscle
atrophy are poorly understood, an imbalance between protein
breakdown and synthesis, in favour of the former, plays an
important role in this process [6]. The ubiquitin-proteasome
system (UPS) is critical for the specific degradation of cellular
proteins, being the main proteolytic system for protein breakdown
in muscular atrophy. UPS induces the expression of the ubiquitin
ligases E3 muscle atrophy F-box (MAFbx, also known as atrogin-1)
and muscle RING finger-1 (MuRF1). These ubiquitin ligases
target proteins with a ubiquitin chain to be subsequently degraded
within the proteasome complex to peptides [7]. Both MAFbx and
MuRF1 have been shown to be up-regulated in different models of
atrophy, conferring them the status of muscle atrophy markers
[8,9]. Another key mediator in protein breakdown during atrophy
is the forkhead box class O (FoxO) family of transcription factors
[10]. In this sense, FoxO1 and FoxO3a, which are highly
expressed in skeletal muscle, induce muscle mass loss by increasing
the expression of MAFbx and MuRF1 [11–13], by inhibiting
muscle growth and differentiation [14] and by impairing the
progression of the cell cycle [15]. On the other hand, the
enhancement of overall protein breakdown is blocked by the Akt
signaling pathway. In its phosphorylated active form, Akt triggers
the phosphorylation/inactivation of FoxO transcription factors,
sequestering them to the cytosol, where they are unable to activate
transcription of MAFbx and MuRF1 [16]. Nonetheless, under
certain conditions, the regulation of Akt and FoxO seems to be
independent of each other [17,18]. Recently, it has been reported
that peroxisome proliferator-activated receptor coactivator 1a
(PGC-1a) also constitutes an important mediator of muscle mass
down-regulating the expression levels and activity of FoxO3a and,
hence, inhibiting muscle atrophy [19].
Obesity and insulin resistance exhibit a derangement in muscle
mass regulation [6]. In this context, leptin has been shown to
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revert the obese and diabetic phenotype of ob/ob mice [20]. Thus,
the aim of our study was to examine the catabolic and anabolic
pathways involved in the regulation of muscle mass of ob/ob mice,
and whether leptin administration normalizes the reduced skeletal
muscle mass of leptin-deficient animals through FoxO-dependent
mechanisms. Data of our study provide evidence that leptin
treatment may increase muscle mass of ob/ob mice by inhibiting
muscular atrophy markers as well as enhancing positive regulators
of muscle cell proliferation.
Results
Leptin Administration Increases Muscle Mass
As expected, undetectable serum leptin concentrations were
found in ob/ob mice. Leptin administration increased leptin levels
in wild type and ob/ob mice. Importantly, the determination of
leptin was performed 20 hours after the last exogenous adminis-
tration of the hormone and measured values were whitin the
nanomolar range observed under physiological circumstances. In
addition, ob/ob mice used in our study were obese, hyperinsulin-
emic, hyperglycemic and hyperlipidemic. Leptin treatment
corrected the obese phenotype and improved glucose and lipid
metabolism of ob/ob mice, independently of the inhibitory effect of
leptin on food intake, as compared to the pair-fed ob/ob group.
Moreover, leptin also decreased body weight and fat mass of wild
type mice independently of appetite reduction (Figure S1). The
biochemical characteristics of wild type and ob/ob mice are
reported in Table S1.
The weights of gastrocnemius (GAS) (P,0.0001), extensor
digitorum longus (EDL) (P,0.0001) and soleus (SOL) (P,0.001)
muscles were significantly lower in ob/ob mice as compared with
wild type, showing a strong effect of leptin deficiency on muscle
mass (Figure 1). In addition, pair-feeding decreased the weight of
GAS in wild type (P,0.05) and ob/ob (P,0.01) mice. Leptin
treatment significantly increased GAS and EDL mass compared to
control (P,0.05) and pair-fed (P,0.01) obese animals and
prevented the SOL mass loss induced by pair-feeding in ob/ob
mice (P,0.05). Leptin administration also increased the weight of
GAS muscle in wild type mice as compared to pair-fed animals
(P,0.01). Curiously, the hormone reduced the weight of EDL in
wild type mice (P,0.05). The cross-sectional area (CSA) of GAS,
EDL and SOL muscle fibers was also decreased in ob/ob compared
to wild type animals (P,0.0001), a condition that was completely
reverted by leptin treatment (P,0.0001). Surprisingly, pair-feeding
Figure 1. Leptin Increases Muscle Mass and Muscle Fiber Size of ob/ob Mice. (A) Gastrocnemius (GAS), extensor digitorum longus (EDL) and
soleus (SOL) muscle weights of PBS (open), pair-fed (gray) and leptin-treated (closed) wild type and ob/ob mice (n = 9–10 per group). *P,0.05,
**P,0.01 and ***P,0.001. (B) Cross-sectional area (CSA) of GAS, EDL and SOL muscle fibers of PBS (open), pair-fed (gray) and leptin-treated (closed)
wild type and ob/obmice (approximately 100 fibers/muscle from 3 mice/group). **P,0.001 and ***P,0.0001. (C) Representative histological sections
of hematoxylin-eosin-stained GAS, EDL and SOL muscles of wild type and ob/ob mice. Scale bars = 200 mm. Results are presented as mean6SEM. G:
genotype, T: treatment.
doi:10.1371/journal.pone.0006808.g001
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increased CSA of EDL and SOL muscle fibers in wild type mice
(P,0.0001), which was not observed in leptin-treated wild type
mice. Therefore, our data show that leptin administration
increases muscle mass and muscle fiber size of ob/ob mice.
Gene Expression Profiles Reveal Significant Changes in
Skeletal Muscle after Leptin Treatment
To investigate the effect of leptin on the catabolic and anabolic
pathways involved in the regulation of the GAS muscle of wild
type and ob/ob mice, their differential gene expression profiles
were analyzed by microarray analysis. The hierarchical clustering
of the gene expression profile in GAS muscle of wild type, ob/ob
and leptin-treated ob/ob mice is shown in Figure S2. Microarray
data showed 1,127 genes with differential expression (1.5-fold
change) for leptin deficiency (wild type vs ob/ob; 51.5% up-
regulated and 48.5% down-regulated genes), 1,546 genes for leptin
administration (ob/ob vs leptin-treated ob/ob mice; 33.1% up-
regulated and 66.9% down-regulated genes), and 1,960 for
appetite inhibiting-independent effects of leptin (pair-fed ob/ob vs
leptin-treated ob/ob group; 50.2% up-regulated and 49.8 down-
regulated genes). The set of genes with altered expression levels
induced by leptin deficiency and administration represents a broad
spectrum of biological processes involved in muscle growth and
atrophy, such as cell cycle progression, ubiquitin-proteolysis and
apoptosis (Tables S2 and S3 in Supporting Information). Our
study shows an up-regulation of positive regulators of muscle
growth and cell cycle progression in GAS muscle of leptin-treated
ob/ob mice (Igf1, Igfbp5, Notch3, Ccnd1, Clk4, Cited4, Cdc14a), and
myoblast differentiation (Eya1, Mkl1, Srf), whereas negative
regulators of cell cycle progression, such as Cdkn1a/p21, Cdkn1b/
p27Kip1 or Rbl2, were down-regulated by leptin administration in
ob/ob mice. Moreover, leptin treatment down-regulated the
expression levels of positive regulators of ubiquitin proteolysis
(Fbxo32/MAFbx, Need4, Ube2h, Ub1x), apoptosis (Acin1, Amid, Dffa,
Bclaf1) and autophagy (Lysmd3, Becn1, Atg121) and up-regulated
inhibitory factors of apoptosis (Apip, Bcl2) (Tables 1 and S2). Leptin
administration also increased the gene expression levels of positive
regulators of protein synthesis (Eif4e, Eefe1) and decreased the
mRNA expression of inhibitors of protein synthesis (Gsk3b, Pten).
Increased gene expression levels codifying for the contractile and
sarcomeric proteins myosin (Myh1/Mhc2x, Myh2/Mhc2a, Myh7/
Mhc1, Myl3, Myl4), troponin (Tnni1, Tnnt1, Tnnc1), tropomyosin
(Tpm3), nebulin (Neb) and titin (Ttn) were normalized by leptin
treatment in ob/ob mice (Tables 1 and S2). Furthermore, leptin
prevented the up-regulation of positive regulators of ubiquitin
proteolysis (Trim63/MuRF1, Fbxo32/MAFbx, Foxo1) and autophagy
(Gabarap11) induced by pair-feeding in ob/ob mice (Table S3).
Microarray data evidenced that leptin is an important regulator of
the expression of genes involved in muscle growth and muscle
atrophy. To confirm the microarray data, the mRNA expression
of a number of representative transcripts involved in muscle
growth and atrophy was analyzed by Real-Time PCR (Figure S3).
Leptin Administration Protects from Muscular Atrophy
No differences in the transcript levels of Foxo1 and Foxo3a in
GAS muscle were detected between wild type and ob/ob mice, but
a tendency towards a down-regulation of both transcription factors
was found after leptin treatment (Figure S3).
Nonetheless, at the protein level, the active form of FoxO3a was
increased (P= 0.012) in ob/ob mice, with the phosphorylated-
FoxO3a (inactive form) being increased by leptin administration
(P= 0.023) in wild type and ob/ob mice (Figure 2A). Thus, since the
activity of FoxO3a is inhibited by phosphorylation, data show that
leptin reduces the functional form of this transcription factor in
GAS muscle of wild type and ob/ob mice. No effect of genotype
(P= 0.833) or leptin treatment (P= 0.279) was observed on the
activity of Akt in GAS muscle of experimental animals (Figure 2B).
On the contrary, the activity of the AMP-activated protein kinase
(AMPK) was increased by leptin treatment in ob/ob mice
(P= 0.033) (Figure 2C). Gene expression studies showed a
significant decrease (P,0.001) in Pgc-1a mRNA levels in GAS
muscle of ob/ob mice (Figure S3). The effect of leptin deficiency on
PGC-1a protein expression showed a similar pattern, being lower
in ob/ob mice compared to wild type mice (P= 0.010). However,
protein expression levels of PGC-1a were significantly increased
(P= 0.005) by leptin administration in skeletal muscle of wild type
and ob/ob mice (Figure 2D).
Leptin treatment decreased the mRNA expression levels of the
atrophy marker MAFbx (P= 0.006) and tended to decrease
MuRF1 in ob/ob mice, although no significant differences were
found for the global effect of treatment (Figure S3 and Table S3).
The protein content of MAFbx (P= 0.014) and MuRF1 (P= 0.021)
was also reduced by leptin treatment in GAS muscle of wild type
and ob/ob mice (Figure 3A). Since MAFbx and MuRF1 proteins
have been associated with myofibrillar protein degradation, their
tissue distribution was analyzed by immunohistochemical analysis.
Fiber sections of GAS muscle showed higher sarcolemmal,
cytosolic and nuclear immunoreactivity of MAFbx and MuRF1
in ob/ob mice as compared to wild type mice and, analogously to
what happened with the protein content, were reduced in the
leptin-treated ob/ob group (Figure 3B). Taken together, these
results suggest that leptin administration decreases protein
expression levels of the atrophy markers MAFbx and MuRFa in
GAS muscle of wild type and ob/ob mice.
Leptin Treatment Enhances Skeletal Muscle Growth
DNA microarray screening showed that leptin administration in
ob/ob mice up-regulates genes involved in muscle growth and cell
cycle in the GAS muscle (Table S2). We examined the effect of
leptin on the protein expression of myostatin, a member of the
transforming growth factor TGFb family, which acts as a negative
regulator of muscle growth [21]. The mature form of myostatin
(22 kDa) was almost undetectable in wild type mice. However,
data showed a high protein expression of myostatin in ob/ob mice,
which was reduced after leptin treatment as compared to the ob/ob
(P= 0.026) and pair-fed ob/ob mice (P= 0.015) (Figure 4A),
suggesting that leptin enhances muscle growth in ob/ob mice.
Myofibers are postmitotic muscle cells being unable to
proliferate. Therefore, postnatal muscle growth depends on
satellite cells, which are localized between the basal lamina and
the plasmatic membrane of muscle fibers. Satellite cells are usually
quiescent but are able to proliferate in response to mitogenic
factors [22,23]. The initiation of the cell cycle depends on the
activity of the complexes of cyclin and cyclin-dependent kinases
(CDK), while FoxO transcription factors inhibit the cell cycle
progression of skeletal muscle by inducing CDK inhibitors [15].
The ob/ob mice showed an increase in the proliferating cell nuclear
antigen (PCNA) (P= 0.010), a marker molecule for proliferating
satellite cells [24,25], and a decrease in cyclin D1 (P= 0.0001)
proteins (Figure 4B). Interestingly, leptin treatment further
increased PCNA as compared to the ob/ob (P = 0.021) and pair-
fed ob/ob (P= 0.003) groups and tended to increase cyclin D1
protein in ob/ob mice (P= 0.055). No significant differences were
found in the protein expression of the CDK inhibitor p27Kip1
(Figure 4B). Given that these regulators of the cell cycle are post-
transcriptionally regulated by phosphorylation, being active within
the nuclei [26–28], immunohistochemical analyses in sections of
GAS muscle were performed to discriminate nuclear and cytosolic
Leptin & Skeletal Muscle Mass
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Table 1. Selected Genes Regulated by Leptin in Gastrocnemius Muscle.
Gene Ontology Biological
Process GeneBank Number Gene Symbol Gene name Fold change
Up-regulated genes
GO: 0007049. Cell cycle
Positive regulators of cell cycle progression
NM_007631 Ccnd1 Cyclin D1 1.217
XM_149387 Cdc14a CDC14 cell division cycle 14 homolog A isoform 1 2.717
NM_019563 Cited4 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 4
2.251
NM_007714 Clk4 CDC like kinase 4 1.503
NM_010512 Igf1 Insulin-like growth factor 1 isoform 1 1.394
NM_010518 Igfbp5 Insulin-like growth factor binding protein 5 1.820
GO: 0019538. Protein metabolic process
Positive regulators of Protein synthesis
NM_025380 Eef1e1 Eukaryotic translation elongation factor 1 e 1 1.359
NM_007917 Eif4e Eukaryotic translation initiation factor 4E 1.454
GO: 45445. Myoblast differentiation
Positive regulators of cell differentiation
BC060260 Eya1 Eyes absent 1 homolog 1.637
AK044188 Mkl1 Myocardin-like 1 1.802
NM_020493 Srf Serum response factor 1.311
GO: 6915. Apoptosis
Negative regulators of apoptosis
NM_019735 Apip APAF1 interacting protein 1.282
NM_009741 Bcl2 B-cell leukemia/lymphoma 2 isoform 1 1.475
Down-regulated genes
GO: 0007049. Cell cycle
Negative regulators of cell cycle
NM_007669 Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 0.612
NM_009875 Cdkn1b Cyclin-dependent kinase inhibitor 1B (P27) 0.472
AK077477 Igfbp3 Insulin-like growth factor binding protein 3 0.542
NM_011250 Rbl2 Retinoblastoma-like 2 0.631
GO: 0006914. Autophagy
Positive regulators of autophagy
NM_026217 Atg12l Autophagy-related 12-like 0.814
NM_030257 Lysmd3 LysM, putative peptidoglycan-binding, domain containing 3 0.655
NM_019584 Becn1 Beclin 1 0.802
GO: 6915. Apoptosis
Positive regulators of apoptosis
NM_023190 Acin1 Apoptotic chromatin condensation inducer 1 isoform 2 0.502
NM_153779 Amid Apoptosis-inducing factor (AIF)-like mitchondrion-associated
inducer of death isoform 1
0.658
NM_007523 Bak1 BCL2-antagonist/killer 1 0.550
NM_153787 Bclaf1 BCL2-associated transcription factor 1 isoform 2 0.543
NM_001025296 Dffa DNA fragmentation factor, a subunit isoform a 0.484
GO: 6511. Ubiquitin-dependent protein catabolism
Positive regulators of ubiquitin-proteolysis
NM_026346 Fbxo32 F-box only protein 32 0.666
NM_010890 Nedd4 Neural precursor cell expressed, developmentally down-regulated
gene 4
0.507
NM_009457 Ube1x Ubiquitin-activating enzyme E1, Chr X 0.414
NM_009459 Ube2h Ubiquitin-conjugating enzyme E2H 0.403
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protein expression. In addition, we assessed immunostaining for
the dystrophin protein, a marker molecule for plasmatic
membrane (Figure 5A), to define positive PCNA nuclei and
discriminate satellite cells from other cell types. In this sense, only
nuclei between the basal lamina and the plasmatic membrane
were counted. Leptin administration increased the nuclear
immunostaining for PCNA (P= 0.002) (Figure 5B) and cyclin D1
(P= 0.005) (Figure 5C) in wild type and ob/ob mice. Moreover,
nuclei of ob/ob mice showed an increased immunostaining of
p27Kip1 (P= 0.002), which was reduced by leptin treatment as
compared to ob/ob (P= 0.004) and pair-fed ob/ob (P= 0.015) mice
(Figure 5D). These data provide evidence that leptin may enhance
cell cycle progression in the GAS muscle of ob/ob mice.
The growth of skeletal muscle requires an increase in the
number of myonuclei together with an increase in the synthesis of
myofibrillar proteins to maintain a constant ratio between number
of nuclei per fiber and fiber size [29,30]. Gene expression analyses
showed up-regulation of genes codifying for contractile and
sarcomeric proteins in the GAS muscle of ob/ob mice, which was
normalized by leptin administration (Figure S3 and Table S2).
Moreover, although a positive regulation of genes involved in the
synthesis of proteins was induced by leptin administration (Table
S2), no effect on the protein expression of both isoforms of MHC
was found (Figure 6A). However, the administration of the
hormone significantly increased the slow and fast isoforms of TnT
in the GAS muscle of wild type and ob/ob mice (Figure 6B). These
data were also confirmed by immunohistochemistry (Figure 6C).
Therefore, leptin increases the protein expression of slow and fast
isoforms of the contractile protein TnT.
Discussion
Muscle loss is the result of a reduced protein synthesis and
increased myofibrillar degradation in response to inactivity, food
deprivation or catabolic diseases [6,31]. Leptin-deficient ob/ob
mice display a reduced skeletal muscle mass [5,32,33] and an
increased muscle proteosome activity [34] compared to their lean
counterparts. Moreover, leptin administration has been shown to
inhibit protein breakdown in C2C12 myotubes [35]. However,
other authors failed to observe any direct effect of leptin on the
synthesis and degradation rates of proteins in skeletal muscle of
rats [36], suggesting that leptin effects on muscle mass may be
mediated by the release of a secondary growth factor. Our study
provides evidence for a myogenic effect of leptin on wild type and
ob/ob mice. The main findings reported herein are that: 1) leptin
induces changes in the expression of transcription factors involved
in muscle growth (reduced FoxO3a and increased PGC-1a); 2)
leptin down-regulates the atrophy markers, MAFbx and MuRF1,
as well as the negative regulator of muscle growth myostatin; and
3) leptin increases the positive cell cycle markers cyclin D1 and
PCNA.
Leptin Inhibits Muscular Atrophy
Animal and human studies have shown that caloric restriction
enhances catabolic pathways in skeletal muscle through the
activation of the energy sensor AMPK, which activates FoxO
transcription factors leading to the up-regulation of MAFbx and
MuRF1 [37–39]. Our results demonstrate that leptin increases the
activity of AMPK in GAS of ob/ob mice as well as decreases the
protein expression of FoxO3a and the mRNA and protein
expression of MAFbx and MuRF1 in wild type and ob/ob mice.
These data suggest that leptin treatment inhibits the catabolic
pathway of proteins mediated by the AMPK. Overexpression of
FoxO3a is sufficient to cause skeletal muscle atrophy by increasing
the UPS activity [11,14], but recent in vivo and in vitro studies have
shown that FoxO3a also activates the autophagic/lysosomal
pathway [12,40]. In this sense, microarray data evidenced that
ob/ob mice presented an upregulation of proteolytic (Need4, Ube2h),
apoptotic (Acin, Amid), and autophagic (Lysmd3, Becn1, Atg121)
genes, which were down-regulated by leptin treatment.
Gene Ontology Biological
Process GeneBank Number Gene Symbol Gene name Fold change
GO: 0019538. Protein metabolic process
Negative regulators of Protein synthesis
NM_010124 Eif4ebp2 Eukaryotic translation initiation factor 4E binding protein 2 0.871
NM_008960 Pten Phosphatase and tensin homolog 0.665
NM_019827 Gsk3b Glycogen synthase kinase 3b 0.464
GO: 45214. Sarcomere organization
Contractile and sarcomeric proteins
XM_354615 Myh1 Myosin, heavy polypeptide 1, skeletal muscle, adult 0.521
NM_144961 Myh2 Myosin, heavy polypeptide 2 0.521
XM_354614 Myh3 Myosin, heavy polypeptide 3, skeletal muscle, embryonic 0.214
NM_080728 Myh7 Myosin, heavy polypeptide 7, cardiac muscle b 0.665
NM_010859 Myl3 Myosin, light polypeptide 3 0.585
NM_010858 Myl4 Myosin, light polypeptide 4 0.688
XM_130232 Neb Nebulin 0.386
NM_021467 Tnni1 Troponin I, skeletal, slow 1 0.438
NM_011618 Tnnt1 Troponin T1, skeletal, slow 0.687
NM_022314 Tpm3 Tropomyosin 3c 0.648
Fold changes between ob/ob vs leptin-treated ob/ob mice of selected differentially expressed genes from Table S2.
doi:10.1371/journal.pone.0006808.t001
Table 1. Cont.
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Figure 2. Leptin Decreases FoxO3a Activity and Increases PGC-1a Protein in Gastrocnemius Muscle. (A) Representative Western blot
analyses of forkhead box class O (FoxO3a) and phospho-FoxO3a proteins of gastrocnemius muscle of PBS (open), pair-fed (gray) and leptin-treated
(closed) wild type and ob/ob mice are shown. b-actin was used as a loading control (n = 8 per group). (B) Representative Western blot analyses of Akt
activity evidenced by phosphorylated-Akt and Akt proteins ratio of gastrocnemius muscle of PBS (open), pair-fed (gray) and leptin-treated (closed)
wild type and ob/ob mice (n = 8 per group). (C) Representative Western blot analyses of AMP-activated protein kinase (AMPK) activity evidenced by
phosphorylated-AMPK and AMPK proteins ratio of gastrocnemius muscle of PBS (open), pair-fed (gray) and leptin-treated (closed) wild type and ob/
ob mice are shown (n= 5 per group). (D) Representative Western blot analyses of AMP- (PGC-1a) of gastrocnemius muscle of PBS (open), pair-fed
(gray) and leptin-treated (closed) wild type and ob/ob mice are shown. b-actin was used as a loading control (n = 8 per group). Data are expressed as
mean6SEM. G: genotype, T: treatment.
doi:10.1371/journal.pone.0006808.g002
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Figure 3. Leptin Decreases MAFbx and MuRF1 Protein Expression in Gastrocnemius Muscle of Wild Type and ob/ob Mice. (A)
Representative Western blot analyses of muscle atrophy F box (MAFbx) and muscle RING finger 1 (MuRF1) proteins of gastrocnemius muscle of PBS
(open), pair-fed (gray) and leptin-treated (closed) wild type and ob/ob mice are shown. b-actin was used as a loading control (n = 8 per group).
*P,0.05. (B) Immunostaining for MAFbx and MuRF1 proteins was assessed by optic microscopy. Representative images are shown for gastrocnemius
muscle. Scale bars = 50 mm. Data are presented as mean6SEM. G: genotype, T: treatment.
doi:10.1371/journal.pone.0006808.g003
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The activation of PI3K/Akt signaling by insulin and growth
factors regulates muscular mass by reducing FoxO3a activity and,
hence, by blocking the expression of MAFbx and MuRF1 [16].
Nonetheless, under certain conditions, regulation of Akt and FoxO
seems to be independent of each other [17,18]. Short-term leptin
treatment activates Akt in smooth [41] and skeletal [42] muscles of
rats, but long-term leptin treatment fails to activate this signaling
pathway in myotubes [43] and in rat GAS muscle [44]. Our results
showed that chronic leptin administration had no effect on Akt
activity, which is in accordance with previous studies [43,44].
PGC-1a protects skeletal muscle from atrophy by blocking
FoxO3a action and atrophy-specific gene transcription [19]. The
transcript levels of PGC-1a are dramatically decreased in models
of mice with muscle atrophy induced by denervation and diabetes
[45], while energy restriction enhances the expression of PGC-1a
in skeletal muscle of rodents and humans [46–48]. Leptin-deficient
ob/ob mice show a markedly reduced expression of Pgc-1a in
brown adipose tissue, which is reverted by leptin treatment [49].
In the present study, we found that leptin deficiency is also
associated with decreased PGC-1a expression in GAS muscle, and
that leptin treatment significantly increased the PGC-1a protein in
GAS muscle of wild type and ob/ob mice, which may be mediated
by AMPK. In fact, AMPK reportedly enhances Pgc-1a up-
regulation in muscle [50,51] and AICAR, an AMPK-activating
agent, leads to marked increases in PGC-1a protein content
[52,53]. Taken together, our findings suggest that leptin inhibits
the pathways leading to muscle atrophy by increasing PGC-1a,
which, in turn, decreases the expression of FoxO3a and its down-
stream effectors, MAFbx and MuRF1 in GAS muscle of wild type
and ob/ob mice.
Leptin Enhances Muscle Growth
Muscle growth is related to a muscle fiber size increase, which
involves a higher content of myofibrillar proteins as well as
number of myonuclei to maintain a constant ratio between
myonuclei per fiber and fiber size [30]. Mitogenic factors enhance
cell cycle progression by increasing the activity of cyclin/CDK
complexes, and inducing nuclear to cytoplasmic translocation of
these inhibitors of cell cycle progression [23]. Moreover, FoxO
proteins also regulate muscular mass by blocking the proliferation
of muscle precursor cells via inhibiting DNA replication and cell
cycle progression through the increase of the negative regulator of
the cell cycle p27Kip1 [15,54]. In this regard, our data show for the
first time that leptin enhances cell cycle progression in GAS muscle
by increasing the activity of the positive regulators of the cell cycle
cyclin D1 and PCNA, and by simultaneously decreasing p27Kip1.
Figure 4. Leptin Regulates Muscle Growth and Cell Cycle Factors. (A) Representative Western blot analyses of myostatin protein of
gastrocnemius muscle of PBS (open), pair-fed (gray) and leptin-treated (closed) wild type and ob/ob mice are shown. b-actin was used as a loading
control (n = 2–6 per group). The myostatin band was detected only in 2 samples of wild type groups.*P,0.05. (B) Representative Western blot
analyses of proliferating cell nuclear antigen (PCNA), cyclin D1 and cyclin-dependent kinase inhibitor 1B (Cdkn1b/p27Kip1) proteins of gastrocnemius
muscle of PBS (open), pair-fed (gray) and leptin-treated (closed) wild type and ob/ob mice are shown. b-actin was used as a loading control (n = 8 per
group). *P,0.05, **P,0.01 and ***P,0.001. Data are expressed as mean6SEM. G: genotype, T: treatment.
doi:10.1371/journal.pone.0006808.g004
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Figure 5. Leptin Enhances Muscle Cell Proliferation. (A) Immunohistochemical staining for dystrophin and PCNA of gastrocnemious muscle of
wild type and ob/ob mice (n = 3 per group). Scale bar = 50 mm. (B) Immunohistochemical staining and relative stained nuclei number for PCNA
evaluated among 500 cells in gastrocnemius muscle of PBS (open), pair-fed (gray) and leptin-treated (closed) wild type and ob/ob mice (n = 3 per
group). Scale bar = 50 mm. **P,0.01. (C) Immunohistochemical staining and relative stained nuclei number for cyclin D1 evaluated among 500 cells
in gastrocnemius muscle of PBS (open), pair-fed (gray) and leptin-treated (closed) wild type and ob/ob mice (n = 3 per group). Scale bar = 50 mm. (D)
Immunohistochemical staining and relative stained nuclei number for p27Kip1 evaluated among 500 cells in gastrocnemius muscle of PBS (open), pair-
fed (gray) and leptin-treated (closed) wild type and ob/ob mice (n = 3 per group). Scale bar = 50 mm. *P,0.05 and **P,0.01. Data are expressed as
mean6SEM. G: genotype, T: treatment.
doi:10.1371/journal.pone.0006808.g005
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Figure 6. Leptin Increases the Expression of Contractile Proteins in Skeletal Muscle. (A) Representative Western blot analyses of myosin
heavy chain type I (MHC I), myosin heavy chain type II (MHC II), slow and fast troponin T (TnT) proteins of gastrocnemius muscle of PBS (open), pair-
fed (gray) and leptin-treated (closed) wild type and ob/ob mice are shown. b-actin was used as a loading control (n = 8 per group). (B)
Immunohistochemical staining for slow and fast troponin T (TnT) of gastrocnemius muscle of wild type and ob/ob mice. Scale bars = 100 mm. Data are
expressed as mean6SEM. G: genotype, T: treatment.
doi:10.1371/journal.pone.0006808.g006
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These findings are in accordance with the mitogenic effects
described for leptin in vascular endothelial cells [55], hepatocytes
[56] cardiomyocytes [57], vascular smooth muscle cells [58], and
myoblasts [59]. Until now, there is little information available on
the effect of leptin on muscle growth in vivo. The work published by
Ruth Harris [60,61] and by Abram M. Madiehe et al. [60,61]
points to an increased protein synthesis and muscle mass in some
strains of db/db mice suggesting that leptin is able to increase the
growth of db/db mice via a mechanism that is dependent on the
short isoform of the leptin receptor.
In order to explore other potential hormonal effects, circulating
concentrations of testosterone were assessed taking into account
that androgenic hormones affect muscle mass. However, no
significant differences were observed following leptin administra-
tion. These data seem to indicate that the leptin effects on muscle
mass observed in the present study are not related to the changes
in testosterone levels. Our findings do not rule out the possibility
that other hormones may be involved in the regulation of muscle
mass of ob/ob mice. It is possible that changes observed in the
leptin-treated mice are related to the overall hormonal changes
elicited by the administration of leptin rather than due to the direct
effects of leptin on muscle mass. In addition, physical activity is a
key regulator for muscle mass and leptin reportedly increases the
reduced spontaneous locomotor activity of ob/ob mice [62,63].
Therefore, the possibility that muscle mass in leptin-treated ob/ob
mice may be affected by physical activity can not be ruled out.
Unfortunately, physical activity was not assessed in the present
study.
It has been suggested that myostatin plays a direct role in the
deterioration of the skeletal muscle in states of obesity and insulin
resistance [64–66]. The biological action of myostatin is well
described in myostatin-deficient mice, which exhibit muscular
hyperplasia and hypertrophy [21,67]. On the contrary, transgenic
mice over-expressing myostatin exhibit a reduced muscular mass
and fiber size [68,69], which has lead to consider myostatin as a
negative regulator of skeletal muscle growth. Interestingly,
myostatin regulates muscle growth by inhibiting the proliferation
[70,71] and differentiation [72,73] of myoblasts. Myostatin
inhibits the progression from the G1 to the S phase in myoblasts
[74], blocks the expression of cyclin D1 and induces its
degradation by the UPS [75,76]. In this respect, a high protein
expression of myostatin was observed in GAS of ob/ob mice in the
present study. Importantly, our data show that leptin decreases the
high myostatin protein expression related to leptin deficiency in
ob/ob mice, suggesting that leptin enhances muscle growth. These
data are consistent with the inhibitory effect of leptin on the high
mRNA myostatin levels in adipose tissue and skeletal muscle of ob/
ob mice previously observed [65].
Fiber size augmentation requires an increase of the myofibrillar
protein content. FoxO1 down-regulates genes implicated in
muscle growth and differentiation [14], and myostatin expression
has been shown to be induced by FoxO1 in myotubes and mice
[77,78]. Moreover, both myostatin and FoxO have been shown to
inhibit protein synthesis by decreasing the activity of the
components of the Akt/mammalian target of rapamycin pathway
[70,79–81]. An unexpected finding of our study was the
discordance for mRNA and protein expression of myofibrillar
MHC and TnT isoforms, which has been suggested to be due to a
higher proteolytic rate or lower translational efficiency, rather than
changes in the transcription process [82–84]. The proteins which
are ubiquitinated by MAFbx, MuRF1 and Need4 remain largely
unknown, but some evidence indicates that MAFbx ubiquitinates
and degradates MyoD [85], Need4 targets Notch [86], and
MuRF1 ubiquitinates and degrades Troponin I [87] and MHC
[84], through a direct role of FoxO1 on the MuRF1 promoter
activity [13]. Our data show that leptin administration prevented
the increase of FoxO3a protein activity and MAFbx and MuRF1
gene and protein expression in wild type and ob/ob mice.
Therefore, the increase of the Mhc1 and Mhc2a and slow TnT
mRNA levels in ob/ob mice in the absence of an increase in their
protein levels may represent a compensatory adaptation to
increase levels of lost myofibrillar proteins in ob/ob mice.
The control of muscle mass is regulated by a dynamic balance
between the anabolic and catabolic processes. Data from our study
indicate, for the first time, that leptin treatment prevents muscular
atrophy by decreasing FoxO3a, MAFbx and MuRF1 protein
expression in relation to an increase in the PGC-1a protein in the
GAS muscle of wild type and ob/ob mice. The reduced skeletal
muscle mass associated to leptin deficiency was prevented by
leptin, on the one hand, reducing the negative regulator of muscle
growth, myostatin, at the same time as by enhancing muscle cell
proliferation through an increase in cyclin D1 and PCNA as well
as the myofibrillar protein content of TnT, while decreasing
p27Kip1.
Unfortunately, except in the rare cases of leptin deficiency, the
clinical application of leptin in humans has not proved to be
worthwhile in common obesity, since most obese patients exhibit
hyperleptinemia pointing to the existence of leptin resistance.
Therefore, no therapeutic benefit as regards improving body
composition in obese humans might be foreseen. Furthermore, the
sexual dimorphism relating to the fact that women have smaller
muscles in spite of increased circulating leptin concentrations and
higher leptin receptors expression should be also contemplated
[88]. Nonetheless, practical applications of leptin administration
may be envisaged in sports medicine and the area of disuse
atrophy, which is a common clinical phenomenon. Prolonged
immobilization due to fractures or neuromotor problems may
represent scenarios for the application of leptin with therapeutic
purposes targeting the restoration of muscle atrophy following
limb disuse. Furthermore, from a physiologic perspective
researchers involved in sports physiology might be also interested
to gain more insight into the regulatory pathways involved in
muscle mass accretion. Moreover, our study suggests that leptin
treatment may be an attractive therapeutic approach to prevent
muscular atrophy associated with catabolic diseases, which might
be particularly useful in cachectic patients, such as frequently
observed in oncological processes, HIV patients as well as other
lipodystrophies.
Materials and Methods
Animals and Treatments
Ten-week-old male wild type (C57BL/6J) (n = 30) and genet-
ically obese ob/ob mice (C57BL/6J) (n = 30) supplied by Harlan
(Barcelona, Spain) were housed in a room with controlled
temperature (2262uC), and a 12:12 light-dark cycle (lights on at
08:00 am). Wild type and ob/ob mice were divided in control,
leptin-treated (1 mg/kg/d) and pair-fed groups (n = 10 per group).
A pilot study with different leptin doses and routes of
administration was carried out in order to select the appropriate
dose to ensure that its concentration would fell within the
physiological range (nanomolar range) in both the wild type and
ob/ob groups. The control and pair-fed groups received vehicle
(PBS), while leptin-treated groups were intraperitoneally admin-
istered with leptin (Bachem, Bubendorf, Switzerland) twice a day
at 08:00 and 20:00 for 28 days. Control and leptin-treated groups
were provided with water and food ad libitum with a standard
rodent chow (2014S Teklad, Harlan, Barcelona, Spain), while the
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daily food intake of the pair-fed groups was matched to the amount
eaten by the leptin-treated groups the day before to discriminate the
inhibitory effect of leptin on appetite. All experimental procedures
conformed to the European Guidelines for the Care and Use of
Laboratory Animals (directive 86/609) and were approved by the
Ethical Committee for Animal Experimentation of the University of
Navarra (080/05). Animals were sacrificed on the 28th day of
treatment by CO2 inhalation 20 h after the last PBS or leptin
administration (in order to avoid picking up effects reflecting an
acute response) and after 8 h of fasting. Serum samples were
obtained and stored at 280uC. Representative muscles of each
muscle fiber type were excised: the SOL muscle is predominantly
composed by oxidative, red fibers; the EDL contains mainly
glycolytic, white fibers; while the GAS represents a mixed muscle
type composed by both red and white fibers. Muscles of one leg
were rapidly dissected out, weighed, frozen in liquid nitrogen, and
stored at 280uC until mRNA and protein extraction, while the
contralateral leg muscles were formalin-fixed for immunohisto-
chemical analyses. Epididymal, perirrenal and subcutaneous
adipose tissue depots were also excised.
Blood Analysis
Serum glucose concentrations were measured using a sensitive-
automatic glucose sensor (Ascensia Elite, Bayer, Barcelona, Spain).
Serum triglycerides were spectrophotometrically determined using
a commercial kit (Infinity, Thermo Electron, Melbourne,
Australia). Serum free fatty acid (FFA) concentrations were
measured by a colorimetric determination using the NEFA C kit
(WAKO Chemicals, Neuss, Germany). Serum glycerol concen-
trations were evaluated by enzymatic methods [89]. Insulin and
leptin were determined using mouse ELISA kits (Crystal Chem
Inc., Chicago, IL, USA). Adiponectin and testosterone concen-
trations were also assessed using ELISA kits (BioVendor
Laboratory Medicine, Inc., Modrice, Czech Republic and R&D
Systems Europe, Ltd., Abingdon, United Kingdom, respectively).
Intra- and inter-assay coefficients of variation for measurements of
insulin, leptin, adiponectin and testosterone were 2.6–4.2% for the
former, and 5.3–8.1%, for the latter.
Microarray Experiments and Analysis
Total RNA was extracted from 20–30 mg of GAS muscle
samples by homogenization with an ULTRA-TURRAXH T 25
basic (IKAH Werke GmbH, Staufen, Germany) using TRIzolTM
reagent (Invitrogen, Barcelona, Spain). Samples were purified
using the RNeasy Mini kit (Qiagen, Barcelona, Spain) and treated
with DNase I (RNase-free DNase Set, Qiagen) in order to remove
any trace of genomic DNA.
Gene expression analyses were conducted using the Agilent
Whole Mouse Genome array (G4121B, Agilent Technologies, Santa
Clara, CA), containing 41,000 mouse genes and transcripts. Briefly,
1 mg of total RNA from each sample was amino-allyl labeled and
amplified using the Amino Allyl MessageAmp II aRNA Amplifica-
tion Kit (Ambion, Austin, TX, USA). Aliquots (1.2 mg) of amplified
aRNA were fluorescently labeled using Cy3/Cy5 (Amersham,
Biosciences, Buckinghamshire, UK) and then appropriately com-
bined and hybridized to Agilent oligomicroarrays. Hybridizations
were performed following a reference design, where control samples
were pools of RNA from all individual samples. Two hybridizations
with fluor reversal (Dye swap) were performed for each sample and 5
animals were used per group. After washing, microarray slides were
scanned using a Gene Pix 4100A scanner (Axon Instruments, Union
City, CA, USA) and image quantization was performed using the
software GenePiX Pro 6.0. Gene expression data for all replicate
experiments were analyzed using the GeneSpring GX software v
7.3.1 (Agilent Technologies). Clustering was accomplished with
the Gene and Condition Tree algorithms. In addition, Gene
Ontology groupings (http://babelomics.bioinfo.cipf.es) and the
KEGG website (http://www.genome.ad.jp/kegg/pathway) were used
in conjunction with GeneSpring (http://www.agilent.com/chem/
genespring) to identify pathways and functional groups of genes. All
microarray data reported are described in accordance with MIAME
guidelines. More information regarding the microarray experiments
can be found at the EMBL-European Bioinformatics Institute
(http://www.ebi.ac.uk/aerep/login. ArrayExpress accession number:
E-MEXP-1831).
Real-Time PCR
To validate the microarray data, a number of representative
differentially expressed genes were selected to be individually
studied by Real-Time PCR (n = 5–10 per group). For first strand
cDNA synthesis, constant amounts of 1.5 mg of total RNA isolated
from GAS muscle were reverse transcribed using random
hexamers (Roche Molecular Biochemicals, Mannheim, Germany)
as primers and 300 units of M-MLV reverse transcriptase
(Invitrogen) as previously described [90]. The transcript levels
were quantified by Real-Time PCR (7300 Real Time PCR
System, Applied Biosystems, Foster City, CA, USA). Primers and
probes were designed using the software Primer Express 2.0
(Applied Biosystems) (Table S4). Probes were designed to
hybridize between exons to ensure the detection of the
corresponding transcript avoiding genomic DNA amplification.
The cDNA was amplified at the following conditions: 95uC for
10 min, followed by 45 cycles of 15 s at 95uC and 1 min at 59uC,
using the TaqManH Universal PCR Master Mix (Applied
Biosystems). The primer and probe concentrations for gene
amplification were 300 nmoL/L and 200 nmoL/L, respectively.
All results were normalized to the levels of 18S rRNA (Applied
Biosystems) and relative quantification was calculated using the
DDCt formula [90]. Relative mRNA expression was expressed as
fold expression over the calibrator sample (average of gene
expression corresponding to the wild type group). All samples were
run in triplicate and the average values were calculated.
Western Blot
Muscle samples (20 mg) were homogenized in RIPA buffer
(1 M Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, EDTA 2H2O 5 mM, 1% deoxycolate) supplemented with
protease inhibitors (CompleteTM Mini-EDTA free, Roche).
Soluble proteins were recovered after centrifugation at 16,000 g
for 15 min at 4uC. Protein concentration was determined
according to the method of Bradford [91] using bovine serum
albumine (BSA) (Sigma, St. Louis, MO, USA) as standard. Equal
amounts of protein (30 mg) were boiled for 10 min and resolved on
10% SDS-PAGE at constant voltage (200 V for 1 h), except for
MHC proteins (100 V for 4 h). Then, proteins were transferred to
nitrocellulose membranes (BioRad, Hercules, CA, USA) and were
blocked with 5% non-fat dry milk in TBS-Tween 20 0.05% for 1 h
at room temperature (RT). Blots were then incubated with mouse
monoclonal anti-PCNA (Dako Cytomation, Glostrup, Denmark),
rabbit polyclonal anti-myostatin, anti-cyclin D1, and anti-p27Kip1
(Abcam, Cambridge, UK), mouse polyclonal anti-MHC I, anti-
MHC II, goat polyclonal anti-PGC-1a, anti-slow TnT, anti-fast
TnT, anti-MAFbx, and rabbit polyclonal anti-MuRF1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal
anti-Akt1/PKB (phospho Thr 308) and anti-Akt1/PKB (Upstate,
Cambridge, UK) antibodies in blocking buffer overnight at 4uC.
After washing with TBS-Tween 0.5% (565 min), membranes
were incubated with horseradish peroxidase-conjugated anti-goat
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IgG (Zymed, San Francisco, CA, USA), anti-rabbit IgG, or anti-
mouse IgG (Amersham Biosciences) for 1 h at RT. Mouse
monoclonal anti-b-actin (Sigma) was used for normalization of
density values. The chemiluminescence ECL reactive (Enhanced
Chemiluminescent System, Amersham Biosciences) was used to
develop the bands, which were analyzed by densitometric analysis
using the Gel Doc-Quantity One 4.5.0. software (Bio-Rad).
Histological Analyses
Sections (5 mm) of formalin-fixed paraffin-embedded muscles were
dewaxed with xylene and hydrated in decreasing concentrations of
ethanol. Endogen peroxidase activity was quenched using 3% H2O2
(Sigma) in absolute methanol for 20 min at RT, and washed 3 times
with ethanol. Sections were immersed in 10 mM citrate buffer
(pH 6.0) and heated using a microwave oven at 800 W for 10 min to
enhance antigen retrieval. After cooling, sections were blocked for
30 min at RT in a humidified chamber with 5% murine or goat
serum (Sigma) in TBS. Polyclonal antibodies against MAFbx,
MuRF1, PCNA, cyclin D1, p27Kip1, fast TnT and slow TnT, used
for immunohistochemistry were the same than those used for
western blot studies. In addition, the dystrophin protein was also
immunolocalized with a monoclonal antibody (Abcam). Sections
were subsequently incubated with the appropriate dilutions of
primary antibodies in TBS with 5% mouse or goat serum (Sigma)
(1:50–100) in a humidified chamber overnight at 4uC. After washing
with TBS (365 min), sections were incubated with horseradish
peroxidase-conjugated secondary antibodies diluted in TBS with 5%
BSA (1:100) for 1 h at RT. After washing with TBS (365 min),
localization of the antigen-antibody binding antibodies was
performed by adding diaminobenzidine (DAB) (Sigma) or DAB
with glucose oxidase (Sigma) as developing system [92]. Negative
control slides with omission of the primary antibodies were included
in the immunostaining procedure. The reaction was stopped and
contrasted with Harris hematoxylin solution (Sigma). Sections were
dehydrated with increasing concentrations of ethanol and xylol,
mounted in DePeX (Panreac, Barcelona, Spain), and observed with
an optic microscope (Axiovert 40 CFL, Zeiss, Go¨ttingen, Germany).
Fiber size was determined by measuring the cross-sectional area of
GAS, SOL and EDL muscle fibers with the Axiovision 4.6 program
(Zeiss). Positive myonuclei for PCNA, cyclin D1 and p27kip1 in cross-
sections of GAS muscles were quantified from 4 microscope fields
(400X) randomly selected. Mean value was expressed as positive
myonuclei number per 100 cells.
Statistical Analysis
Data are expressed as mean6standard error of the mean
(SEM). Global effects of genotype and treatment were determined
using a two-way analysis of the variance (ANOVA). When
interaction between both factors was detected, comparisons
between groups were subsequently analyzed by Kruskal-Wallis
followed by U-Mann Whitney tests. As previously outlined, Gene
Ontology groupings were used to identify pathways significantly
affected by leptin deficiency and administration. Furthermore,
statistical comparisons for microarray data to identify differentially
expressed genes across different groups were performed using one-
way ANOVA and Student’s t-tests as appropriate. All statistical
analyses were performed by using the SPSS statistical program
version 15.0 for Windows (SPSS, Chicago, IL, USA) and statistical
significance was defined as P,0.05.
Supporting Information
Table S1 Biochemical Characteristics of Wild Type and ob/ob
Mice
Found at: doi:10.1371/journal.pone.0006808.s001 (0.03 MB
XLS)
Table S2 Genes Differentially Regulated by Leptin Treatment
in ob/ob Mice
Found at: doi:10.1371/journal.pone.0006808.s002 (0.10 MB
XLS)
Table S3 Genes Differentially Regulated by Leptin Treatment
as Compared to Pair-Feeding in ob/ob Mice
Found at: doi:10.1371/journal.pone.0006808.s003 (0.04 MB
XLS)
Table S4 Sequences of the Primers and Taqman Probes Used in
the Real-Time PCR
Found at: doi:10.1371/journal.pone.0006808.s004 (0.03 MB
XLS)
Figure S1 Leptin Treatment Decreases Body Weight and Body
Fat in Wild Type and ob/ob Mice. (A) Body weight curves of PBS
(open), pair-fed (gray) and leptin-treated (closed) wild type and ob/
ob mice (n = 9–10 animals per group). **P,0.01 and ***P,0.001
for PBS ob/ob vs PBS wild type and leptin-treated ob/ob mice.
+P,0.05, ++P,0.01 and +++P,0.001 for pair-fed ob/ob vs leptin-
treated ob/ob. #P,0.05 and ##P,0.001 for PBS wild type vs
leptin-treated wild type. (B) Daily food intake curves of PBS (open),
pair-fed (gray) and leptin-treated (closed) wild type and ob/ob mice
(n = 9–10 animals per group). ***P,0.001 for PBS ob/ob vs PBS
wild type and leptin-treated ob/ob.#P,0.05 and##P,0.001 for
PBS wild type vs leptin-treated wild type. (C) Epididymal (EWAT),
perirrenal (PWAT) and subcutaneous (SWAT) depots relative to
body weight of PBS (open), pair-fed (gray) and leptin-treated
(closed) wild type and ob/ob mice (9–10 animals per group).
*P,0.05, **P,0.01 and ***P,0.001. Data are presented as
mean6SEM. G: genotype, T: treatment. The striped line indicates
the beginning of the pair-feeding treatment.
Found at: doi:10.1371/journal.pone.0006808.s005 (9.73 MB TIF)
Figure S2 Hierarchical Clustering of the Gene Expression
Profile of the Gastrocnemius Muscle of Wild Type, ob/ob and
Leptin-Treated ob/ob Mice. Red represents up-regulated expres-
sion, green shows down-regulation, and yellow indicates a similar
gene expression pattern as compared to reference. White boxes
highlight that leptin treatment was able to reduce the mRNA
expression of 732 up-regulated genes in ob/ob mice and to increase
the expression of 846 down-regulated genes.
Found at: doi:10.1371/journal.pone.0006808.s006 (10.13 MB
TIF)
Figure S3 Analyses by Real-Time PCR of Key Genes Involved
in Muscular Atrophy and Muscle Growth. (A) Real-Time PCR
analysis of forkhead box class O3a (Foxo3a) and Foxo1, and
peroxisome proliferator-activated receptor coactivator 1a (Pgc-
1a) in gastrocnemius muscle of PBS (open), pair-fed (gray) and
leptin-treated (closed) wild type and ob/ob mice (n = 5 per group).
(B) Real-Time PCR analysis of muscle atrophy F box (MAFbx)
and muscle RING finger 1 (MuRF1) in gastrocnemius muscle of
PBS (open), pair-fed (gray) and leptin-treated (closed) wild type
and ob/ob mice (n = 5 per group). (C) Real-Time PCR analysis of
myosin heavy chain type I (Mhc1), myosin heavy chain type IIa
(Mhc2a), myosin heavy chain type IIb (Mhc2b) and slow
troponin T (slow TnT), in gastrocnemius muscle of PBS (open),
pair-fed (gray) and leptin-treated (closed) wild type and ob/ob
mice (n = 5 per group). Data are presented as mean6SEM of the
ratio between gene expression and 18S rRNA. G: genotype, T:
treatment.
Found at: doi:10.1371/journal.pone.0006808.s007 (0.39 MB TIF)
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